Mesenchymal stem cell-based therapy of liver diseases
Over the past few years, several clinical trials used mesenchymal stem cells to treat patients with liver diseases. Obtained results demonstrated that mesenchymal stem cells treatment improved liver function in safe and well tolerated manner. Amer and colleagues demonstrated the safety and short-term therapeutic effect of autologous transplantation of bone marrow mesenchymal stem cells-derived hepatocyte-like cells in patients with end-stage liver failure. In patients with liver failure caused by hepatitis B virus infection, autologous transplantation of bone marrow-mesenchymal stem cells provided short-term efficacy in respect to several clinical and biochemical parameters, but long-term outcomes were not markedly improved. Recent studies reported that infusion of umbilical-cord derived mesenchymal stem cells was well tolerated in patients with decompensated cirrhosis, and in patients suffering from acute on chronic liver failure, resulting in significant improvement of liver function and increased survival rates.